Targeting Cytokines of the Interleukin-12 Family in Autoimmunity

Author(s): Bok Yun Kang, Tae Sung Kim.

Journal Name: Current Medicinal Chemistry

Volume 13 , Issue 10 , 2006


In the past, autoimmunity was thought to be mediated by antibodies and immune complexes. It has now become clear that many autoimmune diseases, especially tissue specific, are T cell-mediated, or at least T cell-dependent. The pathogenesis of cell-mediated autoimmune diseases, including multiple sclerosis, uveitis, diabetes, arthritis, and others, is now thought to be, in a large measure, driven by interferon-γ-producing, antigen-specific T cells, which are polarized toward the T helper type 1 (Th1) phenotype. Interleukin (IL)-12 and the more recently discovered IL-23 and IL-27 constitute a unique family of structurally-related, heterodimeric cytokines, which regulate cell-mediated immune responses and Th1-type inflammatory reactions. Thus, these cytokines may have a central role in the development and progression of cell-mediated autoimmune diseases. Therefore, pharmacologically targeting cytokines of the IL-12 family would be useful in the modulation of several autoimmune diseases. This review summarizes the recent findings concerning IL-12 family cytokine-mediated autoreactive inflammatory responses, and also describes some possible therapeutic interventions, including medicinal compounds at mitigating autoimmune inflammation.

Keywords: Autoimmunity, Medicinal compounds, IL-12, IL-23, IL-27, T helper cell, Signaling

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1149 - 1156]
Pages: 8
DOI: 10.2174/092986706776360879
Price: $65

Article Metrics

PDF: 6